Literature DB >> 18341624

Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery.

Steven M Lucas1, Robert S Svatek, Guadencio Olgin, Yull Arriaga, Wareef Kabbani, Arthur I Sagalowsky, Yair Lotan.   

Abstract

OBJECTIVE: To compare the outcomes of patients treated for upper tract urothelial carcinoma with either immediate nephroureterectomy (NU) or initial endoscopic management. PATIENTS AND METHODS: The treatments of 108 patients (120 renal units) at the authors' institution were retrospectively reviewed and divided into two groups, i.e. those who received immediate NU and those who had conservative initial therapy, which included renal units solely treated with endoscopy with or without delayed NU. Overall and disease-specific survival (DSS) were compared between the treatment groups.
RESULTS: There were 48 low-grade tumours, of which 27 (56%) were managed conservatively and 21 (44%) by immediate NU. Seven patients treated conservatively had stage or grade progression and had delayed NU. The mean (sd) DSS at 5 years in patients with low-grade disease was equally good for conservative treatment and immediate NU, at 86.2 (9.1)% vs 87.4 (8.4)% (P = 0.909). There were 68 high-grade tumours, of which 12 (18%) patients had conservative management and 56 (82%) had immediate NU. Among the former, seven of 12 had a solitary kidney and three had bilateral disease. In patients managed endoscopically, four of 30 (13%) required delayed NU. The DSS for the conservative and immediate NU groups were 68.6 (18.6)% vs 75.0 (8.1)% (P = 0.528).
CONCLUSION: Management with a conservative approach in selected patients provides comparable outcomes to immediate NU in patients with low-grade disease.

Entities:  

Mesh:

Year:  2008        PMID: 18341624     DOI: 10.1111/j.1464-410X.2008.07535.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  24 in total

1.  Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma.

Authors:  Anil Kapoor; Christopher B Allard; Peter Black; Wassim Kassouf; Christopher Morash; Ricardo Rendon
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

2.  Oncological and renal outcomes of segmental ureterectomy vs. radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  Tomonori Kato; Ryo Nakayama; Tomomi Haba; Makoto Kawaguchi; Akira Komiya; Hiroshi Koike
Journal:  Oncol Lett       Date:  2018-09-19       Impact factor: 2.967

3.  Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years?

Authors:  Mesut Remzi; Shahrokh Shariat; Wilhelm Huebner; Harun Fajkovic; Christian Seitz
Journal:  Ther Adv Urol       Date:  2011-04

Review 4.  Role of lasers in urology.

Authors:  Stephan M Korn; Nicolai A Hübner; Christian Seitz; Shahrokh F Shariat; Harun Fajkovic
Journal:  Photochem Photobiol Sci       Date:  2019-02-13       Impact factor: 3.982

5.  Segmental ureterectomy is not inferior to radical nephroureterectomy for either middle or distal ureter urothelial cell carcinomas within 3.5 cm.

Authors:  Chen Fang; Xin Xie; Tianyuan Xu; Wei He; Hongchao He; Xiaojing Wang; Yu Zhu; Zhoujun Shen; Yuan Shao
Journal:  Int Urol Nephrol       Date:  2017-03-25       Impact factor: 2.370

6.  Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma.

Authors:  Jay Simhan; Marc C Smaldone; Brian L Egleston; Daniel Canter; Steven N Sterious; Anthony T Corcoran; Serge Ginzburg; Robert G Uzzo; Alexander Kutikov
Journal:  BJU Int       Date:  2014-04-03       Impact factor: 5.588

7.  Conservative treatment of upper urinary tract carcinoma: Long-term results.

Authors:  Andrea Orosa Andrada; Inés Laso García; Fernando Arias Fúnez; Francisco Donis Canet; Gemma Duque Ruiz; Victoria Gómez Dos Santos; Francisco Javier Burgos Revilla
Journal:  Can Urol Assoc J       Date:  2017-07-11       Impact factor: 1.862

Review 8.  Upper tract urothelial carcinoma: Paradigm shift towards nephron sparing management.

Authors:  Julia V Fiuk; Brad F Schwartz
Journal:  World J Nephrol       Date:  2016-03-06

9.  Upper tract urothelial carcinoma: impact of time to surgery.

Authors:  Debasish Sundi; Robert S Svatek; Vitaly Margulis; Christopher G Wood; Surena F Matin; Colin P Dinney; Ashish M Kamat
Journal:  Urol Oncol       Date:  2010-09-25       Impact factor: 3.498

10.  Conservative nephron-sparing treatment of upper-tract tumors.

Authors:  Paul Smith; Juliette Mandel; Jay D Raman
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.